You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 56 No. 8, August 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Commentary
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (8)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Statistics and Research Methods
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

The National Bioethics Advisory Commission Report

The Response of the Psychiatric Research Community Is Critical to Restoring Public Trust

Arch Gen Psychiatry. 1999;56:699-700.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE ARTICLE by Oldham et al1 effectively discusses several of the most important criticisms of the National Bioethics Advisory Commission (NBAC) report,2 namely, that the focus on mental disorders stigmatizes patients with mental illness and that the reliance on only 2 levels of risk in determining the degree of protections required may markedly impede psychiatric research. After having reviewed the NBAC report, I still fail to understand why the NBAC believes that a 3-tier level of risk category system such as that described by the New York Advisory Work Group3 is unworkable and unacceptable. In their report, the NBAC writes that they "did not find these concerns convincing" in reference to their proposed 2-tier level of risk. They believed that the

key point is that IRBs [institutional review boards] should focus on the need for a continuous range of protections that are related to the perceived level of risk and . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED ARTICLES

Protection of Persons With Mental Disorders From Research Risk: A Response to the Report of the National Bioethics Advisory Commission
John M. Oldham, Stephan Haimowitz, and Susan J. Delano
Arch Gen Psychiatry. 1999;56(8):688-693.
ABSTRACT | FULL TEXT  

Almost Persuaded: Reactions to Oldham et al
James F. Childress and Harold T. Shapiro
Arch Gen Psychiatry. 1999;56(8):697-698.
EXTRACT | FULL TEXT  

Protecting Vulnerable Research Subjects Without Unduly Constraining Neuropsychiatric Research
Franklin G. Miller and Joseph J. Fins
Arch Gen Psychiatry. 1999;56(8):701-702.
EXTRACT | FULL TEXT  

Reply
John M. Oldham, Stephan Haimowitz, and Susan J. Delano
Arch Gen Psychiatry. 1999;56(8):703-704.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Emerging Empirical Evidence on the Ethics of Schizophrenia Research
Dunn et al.
Schizophr Bull 2006;32:47-68.
ABSTRACT | FULL TEXT  

Meta-Consent in Research on Decisional Capacity: A "Catch-22"?
Saks et al.
Schizophr Bull 2006;32:42-46.
ABSTRACT | FULL TEXT  

National Depressive and Manic-Depressive Association Consensus Statement on the Use of Placebo in Clinical Trials of Mood Disorders
Charney et al.
Arch Gen Psychiatry 2002;59:262-270.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.